

# Luis Alberto Diaz Jr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5784042/publications.pdf>

Version: 2024-02-01

202  
papers

75,252  
citations

4146

87  
h-index

2509

196  
g-index

213  
all docs

213  
docs citations

213  
times ranked

72254  
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	9.4	28
2	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 659-670.	10.7	282
3	Clinical validation of a next-generation sequencing-based multi-cancer early detection "liquid biopsy" blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study. <i>PLoS ONE</i> , 2022, 17, e0266623.	2.5	20
4	Automated next-generation profiling of genomic alterations in human cancers. <i>Nature Communications</i> , 2022, 13, .	12.8	8
5	Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy "Authors' reply. <i>Lancet Oncology</i> , The, 2022, 23, e246.	10.7	1
6	PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2363-2376.	27.0	588
7	Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing?. <i>Annals of Internal Medicine</i> , 2021, 174, 353-361.	3.9	124
8	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. <i>Cancer Cell</i> , 2021, 39, 96-108.e6.	16.8	153
9	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. <i>Nature Communications</i> , 2021, 12, 338.	12.8	64
10	A Decade of <i>Cancer Discovery</i>. <i>Cancer Discovery</i> , 2021, 11, 795-797.	9.4	2
11	CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors. <i>Cancer Discovery</i> , 2021, 11, 1844-1859.	9.4	37
12	The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors. <i>New England Journal of Medicine</i> , 2021, 384, 1168-1170.	27.0	137
13	Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs. <i>Frontiers in Veterinary Science</i> , 2021, 8, 664718.	2.2	21
14	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 665-677.	10.7	110
15	Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. , 2021, 9, e002345.		7
16	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	12.8	68
17	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. <i>Cell</i> , 2021, 184, 4032-4047.e31.	28.9	131
18	Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1686.	7.1	11

#	ARTICLE	IF	CITATIONS
19	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	6.3	66
20	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	1.6	83
21	Clonal hematopoiesis is associated with risk of severe Covid-19. Nature Communications, 2021, 12, 5975.	12.8	81
22	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. JAMA Oncology, 2020, 6, 60.	7.1	112
23	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 2020, 38, 1-10.	1.6	1,740
24	Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. Journal of Clinical Oncology, 2020, 38, 11-19.	1.6	623
25	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Targeted Oncology, 2020, 15, 11-24.	3.6	65
26	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. Scientific Reports, 2020, 10, 17769.	3.3	35
27	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. New England Journal of Medicine, 2020, 383, 2207-2218.	27.0	1,513
28	Chemotherapy and COVID-19 Outcomes in Patients With Cancer. Journal of Clinical Oncology, 2020, 38, 3538-3546.	1.6	195
29	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	21.4	367
30	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clinical Cancer Research, 2020, 26, 3271-3279.	7.0	118
31	Fragment Size Analysis May Distinguish Clonal Hematopoiesis from Tumor-Derived Mutations in Cell-Free DNA. Clinical Chemistry, 2020, 66, 616-618.	3.2	35
32	Evaluation of <i>POLE/POLD1</i> Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes. JAMA Oncology, 2020, 6, 589.	7.1	8
33	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 6160-6169.	7.0	73
34	Hey Ciri, What's My Prognosis? Cell, 2019, 178, 518-520.	28.9	6
35	Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. Journal of Clinical Oncology, 2019, 37, 3546-3555.	1.6	78
36	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. Cancer Immunology Research, 2019, 7, 1574-1579.	3.4	33

#	ARTICLE	IF	CITATIONS
37	Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. Clinical Cancer Research, 2019, 25, 5250-5259.	7.0	46
38	Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates. , 2019, 7, 123.		2
39	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science, 2019, 364, 485-491.	12.6	395
40	Majority of <i>B2M</i> -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. JCO Precision Oncology, 2019, 3, 1-14.	3.0	61
41	Immunotherapy in colorectal cancer: rationale, challenges and potential. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 361-375.	17.8	1,039
42	Managing Clonal Hematopoiesis in Patients With Solid Tumors. Journal of Clinical Oncology, 2019, 37, 7-11.	1.6	60
43	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295.	1.6	397
44	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42
45	Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma. JCO Precision Oncology, 2019, 3, 1-7.	3.0	4
46	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. Clinical Cancer Research, 2019, 25, 7024-7034.	7.0	104
47	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 2019, 25, 1928-1937.	30.7	485
48	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. Modern Pathology, 2019, 32, 110-121.	5.5	28
49	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	12.6	1,872
50	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clinical Cancer Research, 2018, 24, 1326-1336.	7.0	281
51	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science Translational Medicine, 2018, 10, .	12.4	178
52	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. Clinical Cancer Research, 2018, 24, 316-325.	7.0	17
53	Acquired resistance to immunotherapy in MMR-D pancreatic cancer. , 2018, 6, 127.		27
54	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discovery, 2018, 8, 1540-1547.	9.4	138

#	ARTICLE	IF	CITATIONS
55	A machine learning approach for somatic mutation discovery. Science Translational Medicine, 2018, 10, .	12.4	80
56	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. ELife, 2018, 7, .	6.0	118
57	Cancer-Associated Mutations in Endometriosis without Cancer. New England Journal of Medicine, 2017, 376, 1835-1848.	27.0	451
58	Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations. Cancer Discovery, 2017, 7, 188-201.	9.4	997
59	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357, 409-413.	12.6	4,945
60	A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunology Research, 2017, 5, 942-949.	3.4	63
61	Direct detection of early-stage cancers using circulating tumor DNA. Science Translational Medicine, 2017, 9, .	12.4	808
62	Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Medicine, 2017, 6, 1552-1562.	2.8	19
63	The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. Clinical Cancer Research, 2017, 23, 2471-2477.	7.0	154
64	Diagnostic potential of tumor DNA from ovarian cyst fluid. ELife, 2016, 5, .	6.0	30
65	Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 18-26.	1.3	16
66	Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study. Clinical Genitourinary Cancer, 2016, 14, e515-e520.	1.9	19
67	Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. Oncologist, 2016, 21, 1200-1211.	3.7	211
68	Non-infectious environmental antigens as a trigger for the initiation of an autoimmune skin disease. Autoimmunity Reviews, 2016, 15, 923-930.	5.8	26
69	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 2016, 8, 346ra92.	12.4	1,036
70	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal of Medicine, 2016, 375, 1749-1755.	27.0	1,668
71	Overlapping IgG4 Responses to Self- and Environmental Antigens in Endemic Pemphigus Foliaceus. Journal of Immunology, 2016, 196, 2041-2050.	0.8	26
72	PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.. Journal of Clinical Oncology, 2016, 34, 195-195.	1.6	39

#	ARTICLE	IF	CITATIONS
73	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 372, 2509-2520.	27.0	7,696
74	A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1281-1288.	7.0	50
75	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 373, 1979-1979.	27.0	314
76	Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9967-9972.	7.1	41
77	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. <i>Gastroenterology</i> , 2015, 149, 1501-1510.	1.3	376
78	Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 489-498.	2.3	59
79	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. <i>Nature Communications</i> , 2015, 6, 7686.	12.8	393
80	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. <i>Science Translational Medicine</i> , 2015, 7, 293ra104.	12.4	372
81	Genetic Classification of Gliomas: Refining Histopathology. <i>Cancer Cell</i> , 2015, 28, 9-11.	16.8	40
82	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9704-9709.	7.1	317
83	Personalized genomic analyses for cancer mutation discovery and interpretation. <i>Science Translational Medicine</i> , 2015, 7, 283ra53.	12.4	347
84	The genomic landscape of response to EGFR blockade in colorectal cancer. <i>Nature</i> , 2015, 526, 263-267.	27.8	398
85	Lavage of the Uterine Cavity for Molecular Detection of MÅ¼llerian Duct Carcinomas: A Proof-of-Concept Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4293-4300.	1.6	87
86	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	12.4	3,665
87	Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 15-24.	2.8	91
88	A randomized pilot trial of a telephone-based couples intervention for physical intimacy and sexual concerns in colorectal cancer. <i>Psycho-Oncology</i> , 2014, 23, 1005-1013.	2.3	64
89	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11774-11779.	7.1	578
90	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. , 2014, 2, 42.		186

#	ARTICLE	IF	CITATIONS
91	A Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2014, 259, 204-212.	4.2	138
92	Detection of Somatic TP53 Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2014, 124, 881-885.	2.4	44
93	Intratumoral injection of <i>Clostridium novyi</i> -NT spores induces antitumor responses. <i>Science Translational Medicine</i> , 2014, 6, 249ra111.	12.4	285
94	Gastrointestinal ostomies and sexual outcomes: a comparison of colorectal cancer patients by ostomy status. <i>Supportive Care in Cancer</i> , 2014, 22, 461-468.	2.2	51
95	Liquid Biopsies: Genotyping Circulating Tumor DNA. <i>Journal of Clinical Oncology</i> , 2014, 32, 579-586.	1.6	1,811
96	Circulating tumor DNA moves further into the spotlight. <i>Genome Medicine</i> , 2014, 6, 35.	8.2	23
97	Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. <i>Nature Communications</i> , 2014, 5, 5006.	12.8	149
98	The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?. <i>Cancer Research</i> , 2014, 74, 3381-3389.	0.9	207
99	Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. <i>Clinical Cancer Research</i> , 2014, 20, 2476-2484.	7.0	140
100	The Clinical Utility of Biomarkers in the Management of Pancreatic Adenocarcinoma. <i>Seminars in Radiation Oncology</i> , 2014, 24, 67-76.	2.2	13
101	Baseline Hemoglobin-A1c Impacts Clinical Outcomes in Patients With Pancreatic Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 50-57.	4.9	16
102	Tracking tumor resistance using 'liquid biopsies'. <i>Nature Medicine</i> , 2013, 19, 676-677.	30.7	34
103	Cancer Genome Landscapes. <i>Science</i> , 2013, 339, 1546-1558.	12.6	6,507
104	<i>TERT</i> Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine. <i>Cancer Research</i> , 2013, 73, 7162-7167.	0.9	214
105	Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. <i>Cancer</i> , 2013, 119, 4137-4144.	4.1	161
106	The Clinical Potential of Circulating Tumor Cells and Circulating Tumor-Associated Cellular Elements in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 303-311.	0.5	0
107	<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6021-6026.	7.1	1,202
108	Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers. <i>Science Translational Medicine</i> , 2013, 5, 167ra4.	12.4	264



#	ARTICLE	IF	CITATIONS
109	IgG autoantibody subclass analysis as a tool to differentiate epidermolysis bullosa acquisita with overlapping features of bullous systemic lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, e34-e36.	1.2	9
110	Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. <i>Nature Genetics</i> , 2013, 45, 12-17.	21.4	374
111	Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. <i>Investigational New Drugs</i> , 2013, 31, 345-354.	2.6	17
112	Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. <i>Cancer Discovery</i> , 2013, 3, 658-673.	9.4	585
113	Neuroendocrine Liver Metastasis Treated by Using Intraarterial Therapy: Volumetric Functional Imaging Biomarkers of Early Tumor Response and Survival. <i>Radiology</i> , 2013, 266, 502-513.	7.3	54
114	Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer. <i>Journal of Immunotherapy</i> , 2013, 36, 382-389.	2.4	460
115	Evolutionary dynamics of cancer in response to targeted combination therapy. <i>ELife</i> , 2013, 2, e00747.	6.0	516
116	First report of the correlation of PET Response Criteria in Solid Tumors (PERCIST) criteria and pathologic change in patients with rectal cancer treated with neoadjuvant radiation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 261-261.	1.6	1
117	Cancer detection using whole-genome sequencing of cell free DNA. <i>Oncotarget</i> , 2013, 4, 1119-1120.	1.8	11
118	Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. <i>Oncotarget</i> , 2013, 4, 1856-1857.	1.8	39
119	Takotsubo Cardiomyopathy and Fluorouracil: Case Report and Review of the Literature. <i>Journal of Clinical Oncology</i> , 2012, 30, e11-e14.	1.6	72
120	Evaluation of Clostridium novyi NT spores in dogs with naturally occurring tumors. <i>American Journal of Veterinary Research</i> , 2012, 73, 112-118.	0.6	54
121	Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal Cancer. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-12.	0.6	13
122	Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing. <i>Science Translational Medicine</i> , 2012, 4, 162ra154.	12.4	557
123	Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. <i>Journal of Neuro-Oncology</i> , 2012, 110, 279-285.	2.9	29
124	Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. <i>Practical Radiation Oncology</i> , 2012, 2, 77-85.	2.1	28
125	Treating Patients with Colon Cancer Liver Metastasis: A Nationwide Analysis of Therapeutic Decision Making. <i>Annals of Surgical Oncology</i> , 2012, 19, 3668-3676.	1.5	26
126	Frequent <i>ATRX</i> , <i>CIC</i> , <i>FUBP1</i> and <i>IDH1</i> mutations refine the classification of malignant gliomas. <i>Oncotarget</i> , 2012, 3, 709-722.	1.8	532



#	ARTICLE	IF	CITATIONS
127	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature, 2012, 486, 537-540.	27.8	1,506
128	Genetically Defined Subsets of Human Pancreatic Cancer Show Unique <i>In Vitro</i> Chemosensitivity. Clinical Cancer Research, 2012, 18, 6519-6530.	7.0	60
129	Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. Journal of Neuro-Oncology, 2012, 109, 123-127.	2.9	38
130	A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2012, 69, 415-424.	2.3	39
131	A phase I/IIA safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.. Journal of Clinical Oncology, 2012, 30, 233-233.	1.6	2
132	Integrated next-generation sequencing and patient-derived xenografts to personalized cancer treatment.. Journal of Clinical Oncology, 2012, 30, 3068-3068.	1.6	0
133	Diagnosis and Clinical Features of Pemphigus Foliaceus. Dermatologic Clinics, 2011, 29, 405-412.	1.7	99
134	Pathogenesis of Endemic Pemphigus Foliaceus. Dermatologic Clinics, 2011, 29, 413-418.	1.7	22
135	<i>DAXX</i> / <i>ATRX</i> , <i>MEN1</i> , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors. Science, 2011, 331, 1199-1203.	12.6	1,504
136	TNF-blockade in patients with advanced hormone refractory prostate cancer. Investigational New Drugs, 2011, 29, 192-194.	2.6	5
137	Detection of Tumor DNA at the Margins of Colorectal Cancer Liver Metastasis. Clinical Cancer Research, 2011, 17, 3551-3557.	7.0	42
138	Understanding the Enemy. Science Translational Medicine, 2011, 3, 98ps37.	12.4	4
139	Recurrent <i>GNAS</i> Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. Science Translational Medicine, 2011, 3, 92ra66.	12.4	703
140	The C5a Receptor on Mast Cells Is Critical for the Autoimmune Skin-blistering Disease Bullous Pemphigoid. Journal of Biological Chemistry, 2011, 286, 15003-15009.	3.4	66
141	Dual Targets for Mouse Mast Cell Protease-4 in Mediating Tissue Damage in Experimental Bullous Pemphigoid. Journal of Biological Chemistry, 2011, 286, 37358-37367.	3.4	55
142	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21188-21193.	7.1	585
143	Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia. Leukemia, 2011, 25, 1908-1910.	7.2	28
144	IgE, IgM, and IgG4 Anti-Desmoglein 1 Autoantibody Profile in Endemic Pemphigus Foliaceus (Fogo) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	8.7	34

#	ARTICLE	IF	CITATIONS
145	A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles. <i>Oncotarget</i> , 2011, 2, 59-68.	1.8	40
146	IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's Lymphoma patients. <i>Oncotarget</i> , 2011, 2, 178-185.	1.8	61
147	Systemic use of tumor necrosis factor alpha as an anticancer agent. <i>Oncotarget</i> , 2011, 2, 739-751.	1.8	151
148	Disappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned?. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 1691-1700.	1.7	111
149	Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. <i>Nature</i> , 2010, 464, 610-614.	27.8	470
150	The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center. <i>Clinical Cancer Research</i> , 2010, 16, 5997-6003.	7.0	38
151	An Insight into the Sialotranscriptome of <i>Simulium nigrimanum</i> , a Black Fly Associated with Fogo Selvagem in South America. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 82, 1060-1075.	1.4	36
152	Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing. <i>Science Translational Medicine</i> , 2010, 2, 20ra14.	12.4	447
153	The Resident Retreat for Future Academicians. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1775-1777.	0.7	3
154	The Thomsen-Friedenreich Antigen-Binding Lectin Jacalin Interacts with Desmoglein-1 and Abrogates the Pathogenicity of Pemphigus Foliaceus Autoantibodies In Vivo. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2773-2780.	0.7	4
155	p38MAPK Signaling and Desmoglein-3 Internalization Are Linked Events in Pemphigus Acantholysis. <i>Journal of Biological Chemistry</i> , 2010, 285, 8936-8941.	3.4	91
156	Subcutaneous Metastatic Adenocarcinoma: An Unusual Presentation of Colon Cancer – Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2010, 3, 386-390.	0.7	13
157	Frequent Mutations of Chromatin Remodeling Gene <i>ARID1A</i> in Ovarian Clear Cell Carcinoma. <i>Science</i> , 2010, 330, 228-231.	12.6	1,090
158	Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1284-1285.	6.3	79
159	Biphasic Activation of p38MAPK Suggests That Apoptosis Is a Downstream Event in Pemphigus Acantholysis. <i>Journal of Biological Chemistry</i> , 2009, 284, 12524-12532.	3.4	61
160	Involvement of the Apoptotic Mechanism in Pemphigus Foliaceus Autoimmune Injury of the Skin. <i>Journal of Immunology</i> , 2009, 182, 711-717.	0.8	50
161	A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3964-3969.	7.1	267
162	Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. <i>Journal of Neuro-Oncology</i> , 2009, 94, 297-297.	2.9	8

#	ARTICLE	IF	CITATIONS
163	Development of an IgG4-Based Predictor of Endemic Pemphigus Foliaceus (Fogo Selvagem). Journal of Investigative Dermatology, 2009, 129, 110-118.	0.7	47
164	Antigen Selection of Anti-DSG1 Autoantibodies During and Before the Onset of Endemic Pemphigus Foliaceus. Journal of Investigative Dermatology, 2009, 129, 2823-2834.	0.7	22
165	Sensitive digital quantification of DNA methylation in clinical samples. Nature Biotechnology, 2009, 27, 858-863.	17.5	317
166	Glucose Deprivation Contributes to the Development of <i>KRAS</i> Pathway Mutations in Tumor Cells. Science, 2009, 325, 1555-1559.	12.6	797
167	Complement and cutaneous autoimmune blistering diseases. Immunologic Research, 2008, 41, 223-232.	2.9	24
168	An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science, 2008, 321, 1807-1812.	12.6	5,230
169	Circulating mutant DNA to assess tumor dynamics. Nature Medicine, 2008, 14, 985-990.	30.7	2,207
170	Induction of p38MAPK and HSP27 Phosphorylation in Pemphigus Patient Skin. Journal of Investigative Dermatology, 2008, 128, 738-740.	0.7	62
171	The IgM Anti-Desmoglein 1 Response Distinguishes Brazilian Pemphigus Foliaceus (Fogo Selvagem) from Other Forms of Pemphigus. Journal of Investigative Dermatology, 2008, 128, 667-675.	0.7	50
172	E-cadherin Is an Additional Immunological Target for Pemphigus Autoantibodies. Journal of Investigative Dermatology, 2008, 128, 1710-1718.	0.7	56
173	Advances in pemphigus and its endemic pemphigus foliaceus (Fogo Selvagem) phenotype: A paradigm of human autoimmunity. Journal of Autoimmunity, 2008, 31, 311-324.	6.5	86
174	Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. Journal of Autoimmunity, 2008, 31, 331-338.	6.5	120
175	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. Journal of the American Academy of Dermatology, 2008, 58, 1043-1046.	1.2	464
176	Autoantibodies in the Autoimmune Disease Pemphigus Foliaceus Induce Blistering via p38 Mitogen-Activated Protein Kinase-Dependent Signaling in the Skin. American Journal of Pathology, 2008, 173, 1628-1636.	3.8	79
177	Pemphigus Foliaceus. , 2008, 10, 182-194.		14
178	Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins Hospital. Journal of Clinical Oncology, 2008, 26, 3503-3510.	1.6	343
179	Epidemiology and Immunogenetics of Autoimmune Bullous Diseases. Journal of Investigative Dermatology, 2008, 128, E31-E32.	0.7	1
180	Dissecting the Anti-Desmoglein Autoreactive B Cell Repertoire in Pemphigus Vulgaris Patients. Journal of Immunology, 2007, 178, 5982-5990.	0.8	23

#	ARTICLE	IF	CITATIONS
181	Rituximab and Pemphigus " A Therapeutic Advance. New England Journal of Medicine, 2007, 357, 605-607.	27.0	8
182	Serial Assessment of Human Tumor Burdens in Mice by the Analysis of Circulating DNA. Cancer Research, 2007, 67, 9364-9370.	0.9	147
183	Targeting Cancer with Bugs and Liposomes: Ready, Aim, Fire. Cancer Research, 2007, 67, 9605-9608.	0.9	29
184	Endemic Pemphigus Vulgaris. Archives of Dermatology, 2007, 143, 895.	1.4	37
185	Digital quantification of mutant DNA in cancer patients. Current Opinion in Oncology, 2007, 19, 36-42.	2.4	45
186	Imaging of Musculoskeletal Bacterial Infections by [124I]FIAU-PET/CT. PLoS ONE, 2007, 2, e1007.	2.5	86
187	Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid. Archives of Dermatological Research, 2007, 299, 417-422.	1.9	44
188	A Bacterial Protein Enhances the Release and Efficacy of Liposomal Cancer Drugs. Science, 2006, 314, 1308-1311.	12.6	159
189	The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. Nature Biotechnology, 2006, 24, 1573-1580.	17.5	128
190	The colorectal microRNAome. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3687-3692.	7.1	890
191	Contribution of bone marrow"derived endothelial cells to human tumor vasculature. Nature Medicine, 2005, 11, 261-262.	30.7	470
192	Cancer drug discovery through collaboration. Nature Reviews Drug Discovery, 2005, 4, 375-380.	46.4	30
193	Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 2005, 7, 561-573.	16.8	818
194	The current clinical value of genomic instability. Seminars in Cancer Biology, 2005, 15, 67-71.	9.6	13
195	Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16368-16373.	7.1	1,049
196	Desmosome Signaling. Journal of Biological Chemistry, 2005, 280, 23778-23784.	3.4	220
197	Pharmacologic and Toxicologic Evaluation of C. novyi-NT Spores. Toxicological Sciences, 2005, 88, 562-575.	3.1	90
198	Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-Â-D-arabinofuranosyl)-5-iodouracil. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1145-1150.	7.1	125

#	ARTICLE	IF	CITATIONS
199	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3089-3094.	7.1	175
200	Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15172-15177.	7.1	244
201	Reversible Posterior Leukoencephalopathy in an HIV-infected Patient with Thrombotic Thrombocytopenic Purpura. Scandinavian Journal of Infectious Diseases, 2002, 34, 706-709.	1.5	20
202	INDUCTION OF HLA-DR ANTIGEN ON HUMAN SQUAMOUS CARCINOMA BY RECOMBINANT INTERFERON GAMMA. Laryngoscope, 1988, 98, 511-515.	2.0	9